Obesity Emerging Therapies, Unmet Needs & TPP Insights: Thelansis Maps the Landscape

EXECUTIVE SUMMARY
Obesity is no longer a condition treated at the margins of biopharma strategy; it is the defining commercial and clinical battleground of this decade. With over 109 million prevalent cases in the United States alone in 2026, and hundreds of millions more across Europe, Japan, and China, the patient population is vast, the unmet needs are real, and the commercial stakes have never been higher.
What has changed is the science. A generation of treatments that once promised modest efficacy through appetite suppression has given way to a new class of molecules targeting multiple metabolic pathways simultaneously. GLP-1 receptor agonists rewrote the playbook. Triple agonists and amylin combinations are now rewriting it again. The question physicians are asking today is no longer 'can we achieve meaningful weight loss?', it is 'can we make it last, make it accessible, and make it tolerable?'

Thelansis Knowledge Partners has published Obesity - Emerging Therapy, Unmet Needs, and TPP Insights - 2026, a rigorous strategic intelligence report drawing on primary market research conducted with 191 endocrinologists and diabetologists surveyed in March 2026, alongside a comprehensive analysis of the global competitive pipeline, treatment landscape, and physician expectations across the US, EU5, China, and Japan.

Request a Sample of the Obesity - Emerging Therapy, Unmet Needs, and TPP Insights Report 2026: https://thelansis.com/reports/obesity-emerging-therapy-with-unmet-needs-and-tpp-insights-2026/?utm_source=openpr&utm_medium=pressrelease&utm_campaign=obesity_tpp

THE PIPELINE MOMENT: FROM GLP-1 TO THE MULTI-AGONIST ERA
Wegovy and Zepbound have fundamentally reset expectations. Physicians now view 15-20% body weight loss as a realistic clinical target, a figure that would have seemed extraordinary a decade ago. Yet the field is already moving beyond them.
Retatrutide, Eli Lilly's triple incretin agonist, delivered approximately 24% mean weight loss in Phase 2, setting the highest non-surgical efficacy benchmark in the history of obesity pharmacotherapy. CagriSema, Novo Nordisk's combination of cagrilintide and semaglutide, is advancing through pivotal Phase 3 trials and is expected by many physicians to challenge tirzepatide's position. Orforglipron is breaking new ground as the first oral non-peptide GLP-1 receptor agonist to reach Phase 3, with the potential to reach primary care settings and needle-averse patients at scale.
More than 20 Phase 3 programs are now active globally in obesity, spanning subcutaneous and oral routes, novel mechanisms from amylin analogs to MC4R agonists, and indications that extend well beyond weight loss into cardiovascular outcomes, MASH, CKD, and sleep apnea. The pipeline has never been broader, or more consequential.

THE COMMERCIAL OPPORTUNITY: SCALE MEETS PERSISTENT UNMET NEED
Obesity pharmacotherapy is already a multi-billion-dollar market. But current therapies, transformative as they are, leave physicians and patients facing challenges that no approved treatment has yet fully solved.
Weight regain after stopping therapy was the second most cited unmet need across all surveyed markets, flagged by 71% of US physicians and 66% in Europe as insufficiently addressed by current options. Treatment affordability and reimbursement access topped the global rankings, cited by 72% of US physicians and 81% in China. These are not abstract concerns; they are the structural forces shaping prescribing behavior and limiting real-world impact.
For companies entering this space with differentiated mechanisms, meaningfully better tolerability, or more convenient dosing, the commercial rationale is compelling. The Thelansis 2026 Obesity report maps these dynamics with granularity, covering physician attitudes, therapy positioning by line and geography, primary market research outcomes, target product profile expectations, and unmet need prioritization across global markets.

Explore the Full Commercial Roadmap, Country-level Datasets, and Physician Insights - Request Free Sample of Obesity - Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026: https://thelansis.com/reports/obesity-emerging-therapy-with-unmet-needs-and-tpp-insights-2026/?utm_source=openpr&utm_medium=pressrelease&utm_campaign=obesity_tpp

KEY EMERGING PLAYERS IN THE OBESITY PIPELINE
The obesity competitive landscape spans over 20 active Phase 3 programs and a deep Phase 2 bench, representing the broadest and most mechanistically diverse pipeline in the disease's commercial history. Key players shaping the next chapter of obesity treatment include: Eli Lilly Retatrutide, Novo Nordisk CagriSema, Eli Lilly Orforglipron, Amgen Maridebart Cafraglutide (MariTide), Boehringer Ingelheim Survodutide, Viking Therapeutics VK2735, Rhythm Pharmaceuticals Setmelanotide.

Note: The above represents a selection of late-phase programs. The full report profiles additional Phase 3 and Phase 2 pipeline assets.

CURRENT STANDARD OF CARE
Across all major markets, the dominant treatment approach is lifestyle modification combined with pharmacotherapy, a pattern cited by 60-75% of surveyed physicians globally. GLP-1 receptor agonists, particularly semaglutide (Wegovy) and tirzepatide (Zepbound/Mounjaro), have become the clinical benchmark against which all pipeline candidates are evaluated. Older agents such as orlistat, phentermine, and combination oral options remain in use in certain markets but have lost clinical relevance against the efficacy of next-generation incretins.
Even so, the limitations of current therapy are felt daily in clinical practice. Gastrointestinal adverse events remain the leading driver of non-adherence and dose discontinuation. Weight regain after stopping therapy is pervasive. And for many patients in Europe, China, and Japan, cost and reimbursement constraints mean the best available therapies remain out of reach. The next generation of obesity drugs will be judged not just on what they can achieve in a trial, but on how well they address what current therapies cannot.

KEY MARKET DRIVERS & EVOLUTION TRENDS
• Next-Generation Efficacy Raising the Bar: Triple agonists and dual-agonist combinations are redefining what effective obesity treatment can achieve in clinical practice.
• Oral GLP-1 Innovation Expanding Market Access: Non-peptide oral agents are opening the door for primary care prescribing and reaching patients who have long resisted injectable therapy.
• Durability Becoming the New Efficacy Standard: Long-term weight maintenance, not just peak reduction, is what physicians and payers now want to see in clinical programs.
• Comorbidity-Focused Outcomes Gaining Priority: Cardiovascular outcomes, MASH benefit, CKD, and OSA are becoming critical differentiators across prescribing decisions and payer negotiations.
• Lean Mass Preservation Emerging as a Key TPP Attribute: Selective fat loss without muscle loss is increasingly central to product design and physician expectations.
• Regional Pipeline Divergence Shaping Global Strategy: A robust wave of domestically developed agents in China is positioning local players for volume-driven market share, while EU access constraints favor oral and well-tolerated options.
• Treatment Paradigm Shifting Toward Chronic Disease Management: Obesity is being reframed as a lifelong metabolic disease requiring durable, patient-friendly treatment, not episodic intervention.
• Affordability and Reimbursement Constraining Real-World Impact: Even the most effective approved therapies are underutilized because of cost and payer access, this is an opportunity that differentiates on access, not just efficacy.

Understand Market Drivers, Physician Positioning & Country-Level Trends in Full Depth - Explore the Report: https://thelansis.com/reports/obesity-emerging-therapy-with-unmet-needs-and-tpp-insights-2026/?utm_source=openpr&utm_medium=pressrelease&utm_campaign=obesity_tpp

KEY UNMET NEEDS & KOL EXPECTATIONS
• Weight Regain After Discontinuation: The absence of durable off-therapy weight maintenance remains the most clinically frustrating gap in current treatment. Physicians describe the cycle of regain as demoralizing for patients and a barrier to long-term engagement.
• GI Tolerability Across All Geographies: Nausea and vomiting-related discontinuation are class-wide issues. The next generation must offer meaningfully improved tolerability, not marginal improvement.
• Effective Oral Options: Physicians globally are seeking oral agents that deliver GLP-1-class efficacy without the complexity of current oral formulations or the inconvenience of injections.
• Lean Mass Preservation: As attention shifts from total weight to body composition, therapies that selectively reduce fat while protecting muscle are becoming a valued clinical differentiator.
• Comorbidity Benefit Beyond the Scale: KOLs across all markets expect emerging therapies to demonstrate meaningful impact on cardiovascular risk, glycemic control, and metabolic health, not weight reduction alone.
• Long-Term Real-World Adherence: Trial efficacy rarely translates fully to real-world persistence. Simpler dosing, better tolerability, and patient-friendly administration are as commercially important as peak efficacy.
• Clearer Reimbursement and Market Access Pathways: Particularly in Europe, China, and Japan, payer alignment is as critical as clinical differentiation in determining the commercial trajectory of new entrants.

Get Emerging Therapy Profiles, KOL Insights & TPP Analysis - Access the Full Report: https://thelansis.com/reports/obesity-emerging-therapy-with-unmet-needs-and-tpp-insights-2026/?utm_source=openpr&utm_medium=pressrelease&utm_campaign=obesity_tpp

Contact Information:
Himanshi Negi
Manager - Global BD & Partnering, Thelansis Knowledge Partners
Email: n.himanshi@thelansis.com
Phone: +91-9560149525
Website: www.thelansis.com
Platform: https://epilansis.com/
General inquiries: clientsupport@thelansis.com

About Thelansis:
Thelansis is a specialized healthcare market intelligence and consulting firm serving global pharmaceutical, biotechnology, and life sciences organizations. Through rigorously researched market reports, subscription-based intelligence solutions, and customized consulting engagements, Thelansis helps clients make informed decisions across the product lifecycle, from early pipeline strategy and opportunity assessment to market access and commercial launch.

The company's rare disease research portfolio spans more than 450 indications, covering epidemiology modeling, competitive intelligence, market forecasting, treatment landscape assessment, and unmet need analysis. Its insights are built on a foundation of primary KOL interviews, real-world evidence, proprietary analytical frameworks, and continuous monitoring of global healthcare markets.

In addition, Thelansis offers EpiLansis, an AI-powered cloud intelligence platform that enables interactive exploration of patient populations, epidemiology trends, treatment utilization, and market dynamics across multiple therapeutic areas.

This release was published on openPR.